This HTML5 document contains 214 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.1371/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q35117549
rdf:type
wikibase:Item
schema:description
article scientifique (publié 2014) artykuł naukowy artikulong pang-agham articol științific videnskabelig artikel (udgivet 2014) наукова стаття, опублікована в березні 2014 2014年论文 מאמר מדעי artículu científicu espublizáu en 2014 мақолаи илмӣ 2014年论文 2014年論文 სამეცნიერო სტატია tieteellinen artikkeli artigo científico 2014 nî lūn-bûn naučni članak мақолаи илмӣ научни чланак 2014年论文 2014年論文 научна статия artigo científico (publicado na 2014) 2014年の論文 مقالهٔ علمی wissenschaftlicher Artikel article científic 2014 թուականի Մարտին հրատարակուած գիտական յօդուած 2014年論文 tudományos cikk artigo científico (publicado na 2014) مقالة علمية mokslinis straipsnis artikull shkencor scientific article επιστημονικό άρθρο teaduslik artikkel 2014年论文 vetenskaplig artikel 2014年论文 artículo científico publicado en 2014 articolo scientifico scienca artikolo vitenskapelig artikkel article scientific bài báo khoa học 2014年論文 2014년 논문 научная статья บทความทางวิทยาศาสตร์ سائنسی مضمون vedecký článok wetenschappelijk artikel vědecký článek научни чланак vitskapeleg artikkel 2014 թվականի մարտին հրատարակված գիտական հոդված 2014年论文 2014年論文 bilimsel makale ২০১৪-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ
p:P577
wds:Q35117549-39F235A5-C359-4467-AEF9-7A85B24205E1
wdt:P577
2014-03-11T00:00:00Z
p:P407
wds:Q35117549-9F4C9A8C-B7FA-42BF-BF8C-63B104B5FE99
wdt:P407
wd:Q1860
p:P2860
wds:Q35117549-F2209126-CA94-4407-8E4B-62948E46C27C wds:Q35117549-F26EB353-2130-4197-92CE-B3B9F1743BB1 wds:Q35117549-FA9A1257-81AF-49FC-8772-12C40DD168D3 wds:Q35117549-DF04CDEB-4CF6-4D5B-AF06-853BB9D6BBD0 wds:Q35117549-ED6C06C5-F9E2-4079-9E82-8FB94BFDC61D wds:Q35117549-D37A44CF-AC6F-4C4D-A64F-308E38C68682 wds:Q35117549-D5334BAB-83B8-45BD-AE8B-E7BE72A2442B wds:Q35117549-DECDF973-C01A-46B3-9EB9-859D3FF923D9 wds:Q35117549-D02DEF4E-4C67-4166-9360-8A4B120C546F wds:Q35117549-D34CF204-839F-4919-8174-3355B3D98155 wds:Q35117549-BAFACF57-4A3E-42B4-9A13-0D2180803048 wds:Q35117549-BB389EFC-3A04-49F2-8AE1-3A1B7B198E57 wds:Q35117549-C13B3279-1E8B-4FFF-B91C-59ED6561D725 wds:Q35117549-C9EDC1D7-1D99-4992-BBE2-82C772916883 wds:Q35117549-B0AE4F13-A8C0-404A-8305-316F2B197AAD wds:Q35117549-B30FE799-302F-4E6A-A5D4-62CE0CFB0372 wds:Q35117549-B6054323-561A-4B8B-B087-0CAF048A4CD7 wds:Q35117549-AB6EB36A-053D-47A0-AAA6-87A26F4DE73E wds:Q35117549-ABE9C076-5B69-4EE8-AB30-A6C3988F9599 wds:Q35117549-A3A66DB4-4A56-4485-AA0B-3E64B3109B21 wds:Q35117549-A3F7054B-1848-457B-BC68-97D188C6CEB7 wds:Q35117549-A4A398E0-B613-4E16-A29F-86AD0545B57D wds:Q35117549-9CE679EE-B94B-4E42-BC47-B389FF027FC0 wds:Q35117549-9E500118-47E7-42DB-9540-CADFAED702E9 wds:Q35117549-8991136A-BAA3-43F2-9AB9-B12C153E89E0 wds:Q35117549-807A7D2B-ED96-4CCA-B4C3-D01A195C3B38 wds:Q35117549-8646C36D-D268-40B7-A843-115F8CF7A143 wds:Q35117549-885C9450-79C4-482F-991E-1F0BBE8C3E6F wds:Q35117549-66B45D68-6849-4C1C-A6BD-0F71E2A12AA1 wds:Q35117549-6BF7A7A4-AD1B-4C28-91CF-B404B38B2D3C wds:Q35117549-4981A24C-FCE3-4909-A96D-AF42C4578DD4 wds:Q35117549-4D361B5C-02B0-4798-A549-A39DC995682D wds:Q35117549-5DA75EE8-F0CB-4DC5-9459-2800BF9E7E7C wds:Q35117549-45BB47A0-9E61-4893-A082-6D177370D412 wds:Q35117549-45C61415-BCE4-47BB-B806-64A838DBF961 wds:Q35117549-45F82ACC-1B7B-48EA-9292-C150C9885B61 wds:Q35117549-48EFCEC5-DE82-405E-8C09-CE9BB042713C wds:Q35117549-3D5240BD-DA81-4C17-8713-2C82938EB347 wds:Q35117549-23BDBF39-D20E-490C-B281-AFCA1CAAE559 wds:Q35117549-23EA709F-7CFB-413D-B199-58A81409CBD6 wds:Q35117549-2A12E610-82FB-4692-BB82-38F2BF62D87A wds:Q35117549-2A493839-7A7B-4402-9B24-06ECD5D10AF1 wds:Q35117549-1292B4FE-43B1-4979-9304-2037B3F53689 wds:Q35117549-1B104914-5C30-4C49-B63C-5EC3EF649EDF wds:Q35117549-065A2550-F7C8-4C3A-9842-79D57C1028C3 wds:Q35117549-10C2255A-DC4C-4B4E-8135-01C93932BA66
wdt:P2860
wd:Q47694886 wd:Q41494312 wd:Q71601446 wd:Q71542471 wd:Q42978485 wd:Q36872021 wd:Q42520359 wd:Q24631953 wd:Q36944384 wd:Q38502534 wd:Q33933880 wd:Q37219226 wd:Q38337029 wd:Q24658224 wd:Q57578467 wd:Q35149292 wd:Q51026241 wd:Q47733204 wd:Q77677069 wd:Q37438563 wd:Q60609530 wd:Q28473783 wd:Q36366470 wd:Q28288866 wd:Q37048061 wd:Q83226640 wd:Q41314907 wd:Q71032360 wd:Q37048053 wd:Q27860904 wd:Q34694524 wd:Q34795604 wd:Q37830876 wd:Q73209070 wd:Q35669295 wd:Q34616814 wd:Q28275478 wd:Q36371536 wd:Q36983438 wd:Q28742851 wd:Q35692166 wd:Q35641963 wd:Q54690366 wd:Q33581597 wd:Q45930106 wd:Q77164555
p:P2093
wds:Q35117549-6F497631-CEEB-40FD-B83A-78BC625C70DE wds:Q35117549-5FC9658D-A6BB-468E-AC9F-2907D19B7D0D wds:Q35117549-CA056C4F-0B4E-46EB-8E8C-4E45CEA3E4C9 wds:Q35117549-A7F032F8-AEA7-408C-A09A-F3DE7E46978F wds:Q35117549-B58F1410-4680-4406-9A49-D88B4FAE4CFD wds:Q35117549-F4EF88C5-C805-403A-9277-54749856BE81 wds:Q35117549-D54BDBB9-9461-4945-813D-6702747E38BB
wdt:P2093
Bruce J Dezube John C Morris Thomas E Olencki Frank J Hsu Donald P Lawrence Antoinette R Tan Geoffrey I Shapiro
rdfs:label
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma
skos:prefLabel
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma
schema:name
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma
p:P50
wds:Q35117549-EF9B7437-E558-4856-B0C3-3BCC286936EE wds:Q35117549-13D2B5AB-6FAE-4761-8ABD-C5E195D62597
wdt:P50
wd:Q61160082 wd:Q56547220
p:P1476
wds:Q35117549-DF011E2A-FF65-40B2-AB43-0E089873DC36
wdt:P1476
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma
p:P304
wds:Q35117549-AF815D06-5EFF-46CE-A7B3-9AF8E82C3490
wdt:P304
e90353
p:P31
wds:Q35117549-90B18C44-9826-4EB1-A0E1-A70B7B3D27F3
wdt:P31
wd:Q13442814
p:P921
wds:Q35117549-11651BA5-1005-4A04-B91A-74BF229A742B wds:Q35117549-1245ED70-91F3-405A-8F0A-C6D981894FBD
wdt:P921
wd:Q422248 wd:Q79460
p:P698
wds:Q35117549-99C26F28-74CF-4108-B079-97F6ED1E1559
wdtn:P698
n11:24618589
wdt:P698
24618589
p:P1433
wds:Q35117549-103C64B0-5884-4BE0-95CB-8F9205603E81
wdt:P1433
wd:Q564954
p:P433
wds:Q35117549-934E1DDF-A207-467A-9581-E6D7C29849F1
p:P478
wds:Q35117549-93DDDDEB-5CB7-45E1-A89D-10505B5E42EC
wdt:P433
3
wdt:P478
9
p:P356
wds:Q35117549-7677AC10-A0CA-4FAE-90F1-B154235E9C9C
wdtn:P356
n12:JOURNAL.PONE.0090353
wdt:P356
10.1371/JOURNAL.PONE.0090353
p:P275
wds:Q35117549-90d09822-de47-43ce-aea5-51e5fb76289e
p:P6216
wds:Q35117549-3709e282-d30e-4bac-ae06-7d808707713a
wdt:P275
wd:Q6938433
wdt:P6216
wd:Q88088423
p:P5875
wds:Q35117549-4C4C534C-D6D4-432C-83AE-7A08CC59073F
wdt:P5875
260717253
p:P819
wds:Q35117549-3A1C0ABF-79AF-40B2-87DC-02B604AB4691
wdt:P819
2014PLoSO...990353M
p:P932
wds:Q35117549-CF9259D9-17A3-4575-9B15-0AE13F1A89F5
wdt:P932
3949712